Glycemic targets: what is the evidence?
Silvio Inzucchi1, Sachin Majumdar2
1Department of Endocrinology, Yale University School of Medicine, New Haven, CT; Medical Director, Yale Diabetes Center, Yale-New Haven Hospital, New Haven, CT.
The Medical Clinics of North America
|December 3, 2014
Summary
High blood sugar (hyperglycemia) is central to diabetes. This review examines if controlling hyperglycemia prevents diabetes complications, supporting the glucose hypothesis for better patient outcomes.
Area of Science:
- Endocrinology
- Metabolic Diseases
- Clinical Research
Background:
- Hyperglycemia is a key characteristic of all diabetes mellitus types.
- Epidemiologic data link hyperglycemia to diabetes complications.
- The glucose hypothesis posits that hyperglycemia causes these complications.
Purpose of the Study:
- To review the relationship between hyperglycemia and diabetes complications.
- To analyze major glucose-lowering trials.
- To evaluate the evidence supporting the glucose hypothesis and its clinical application.
Main Methods:
- Review of epidemiologic studies on hyperglycemia and diabetes complications.
- Analysis of data from major clinical trials focused on glucose-lowering interventions.
- Synthesis of evidence to assess the validity of the glucose hypothesis.
Main Results:
- Strong associations exist between hyperglycemia and diabetes complications.
- Glucose-lowering interventions show varying degrees of success in preventing complications.
- The extent to which the glucose hypothesis is supported varies across different complications and interventions.
Conclusions:
- Hyperglycemia plays a significant role in the development of diabetes complications.
- Effective glucose control is crucial for managing diabetes and preventing long-term complications.
- Translating research findings into clinical practice requires careful consideration of individual patient needs and evidence from glucose-lowering trials.
Related Concept Videos
01:15Hypoglycemia and Glucagon
1.4K
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
1.4K
01:15Diabetes: Management and Pharmacotherapy
1.5K
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
1.5K
01:29Hyperglycemia
2
Hyperglycemia is an abnormally high blood glucose level. It is diagnosed by fasting glucose ≥126 mg/dL, 2-hour oral glucose tolerance test (or OGTT) ≥200 mg/dL, random glucose ≥200 mg/dL with symptoms, or HbA1c ≥6.5%. However, HbA1c results may be unreliable in certain conditions, such as anemia or hemoglobinopathies, and the diagnosis should be confirmed unless classic symptoms are present. Postprandial hyperglycemia is typically considered significant when glucose...
2
01:25Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis
4
Type 2 diabetes mellitus develops gradually and is often asymptomatic in early stages.Clinical ManifestationsWhen symptoms appear, they include fatigue, blurred vision, pruritus, delayed wound healing, and recurrent infections, particularly candidal infections. Peripheral neuropathy may present as numbness or tingling in the extremities. Classic hyperglycemia symptoms—polyuria, polydipsia, and polyphagia—are less common. Most patients are overweight and frequently have associated...
4
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
921
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
921
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
1.0K
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
1.0K